The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT

被引:85
|
作者
Beheshti, Mohsen [1 ]
Poecher, Sigrid [1 ]
Vali, Reza [1 ]
Waldenberger, Peter [2 ]
Broinger, Gabriele [3 ]
Nader, Michael [1 ]
Kohlfuerst, Susanne [4 ]
Pirich, Christian
Dralle, Henning
Langsteger, Werner [1 ]
机构
[1] St Vincents Hosp, Dept Nucl Med & Endocrinol, PET CT Ctr LINZ, A-4020 Linz, Austria
[2] St Vincents Hosp, Dept Radiol, A-4020 Linz, Austria
[3] St Vincents Hosp, Dept Clin Pathol, A-4020 Linz, Austria
[4] Gen Hosp, Dept Nucl Med & Special Endocrinol, Klagenfurt, Austria
关键词
PET-CT; F-18-DOPA; F-18-FDG; Medullary thyroid carcinoma; POSITRON-EMISSION-TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; ELEVATED CALCITONIN LEVELS; PROGNOSTIC-FACTORS; NEUROENDOCRINE TUMORS; NODE DISSECTION; BIOCHEMICAL-EVIDENCE; HEPATIC METASTASES; CANCER; RECURRENT;
D O I
10.1007/s00330-008-1280-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of this prospective study was to compare the value of DOPA PET-CT with FDG PET-CT in the detection of malignant lesions in patients with medullary thyroid carcinoma (MTC). Twenty-six consecutive patients (10 men, 16 women, mean age 59 +/- 14 years) with elevated calcitonin levels were evaluated in this prospective study. DOPA and FDG PET-CT modalities were performed within a maximum of 4 weeks (median 7 days) in all patients. The data were evaluated on a patient- and lesion-based analysis. The final diagnosis of positive PET lesions was based on histopathological findings and/or imaging follow-up studies (i.e., DOPA and/or FDG PET-CT) for at least 6 months (range 6-24 months). In 21 (21/26) patients at least one malignant lesion was detected by DOPA PET, while only 15 (15/26) patients showed abnormal FDG uptake. DOPA PET provided important additional information in the follow-up assessment in seven (27%) patients which changed the therapeutic management. The patient-based analysis of our data demonstrated a sensitivity of 81% for DOPA PET versus 58% for FDG PET, respectively. In four (4/26) postoperative patients DOPA and FDG PET-CT studies were negative in spite of elevated serum calcitonin and CEA levels as well as abnormal pentagastrin tests. Overall 59 pathological lesions with abnormal tracer uptake were seen on DOPA and/or FDG PET studies. In the final diagnosis 53 lesions proved to be malignant. DOPA PET correctly detected 94% (50/53) of malignant lesions, whereas only 62% (33/53) of malignant lesions were detected with FDG PET. DOPA PET-CT showed superior results to FDG PET-CT in the preoperative and follow-up assessment of MTC patients. Therefore, we recommend DOPA PET-CT as a one-stop diagnostic procedure to provide both functional and morphological data in order to select those patients who may benefit from (re-)operation with curative intent as well as guiding further surgical procedures.
引用
收藏
页码:1425 / 1434
页数:10
相关论文
共 50 条
  • [1] The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
    Mohsen Beheshti
    Sigrid Pöcher
    Reza Vali
    Peter Waldenberger
    Gabriele Broinger
    Michael Nader
    Susanne Kohlfürst
    Christian Pirich
    Henning Dralle
    Werner Langsteger
    European Radiology, 2009, 19 : 1425 - 1434
  • [2] Comparison of 18F-DOPA, 68Ga-Somatostatin Analogues and 18F-FDG PET-CT in Patients with Recurrent Medullary Thyroid Carcinoma
    Treglia, G.
    Castaldi, P.
    Villani, M. F.
    Filice, A.
    Ambrosini, V
    Cremonini, N.
    Salvo, D.
    Fanti, S.
    Rufini, V
    NEUROENDOCRINOLOGY, 2011, 94 : 48 - 48
  • [3] Complementary Roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in Medullary Thyroid Cancer
    Kauhanen, Saila
    Schalin-Jantti, Camilla
    Seppanen, Marko
    Kajander, Sami
    Virtanen, Sami
    Schildt, Jukka
    Lisinen, Irina
    Ahonen, Aapo
    Heiskanen, Ilkka
    Vaisanen, Mika
    Arola, Johanna
    Korsoff, Pirkko
    Ebeling, Tapani
    Sane, Timo
    Minn, Heikki
    Valimaki, Matti J.
    Nuutila, Pirjo
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 1855 - 1863
  • [4] The value of 18F-FDG PET/CT and 18F-DOPA PET/CT in determining the initial surgical strategy of patients with medullary thyroid cancer: Preoperative PET/CT imaging for medullary thyroid cancer
    Jager, Eline C.
    Brouwers, Adrienne H.
    Metman, Madelon J. H.
    Aykan, Dilay
    de Vries, Lisa H.
    Lodewijk, Lutske
    Vriens, Menno R.
    Kruijff, Schelto
    Links, Thera P.
    CANCER IMAGING, 2025, 25 (01)
  • [5] Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
    Naswa, Niraj
    Sharma, Punit
    Suman, Sudhir K. C.
    Lata, Sneh
    Kumar, Rakesh
    Malhotra, Arun
    Bal, Chandrasekhar
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (07) : 766 - 774
  • [6] Clinical Relevance of 18F-FDG PET and 18F-DOPA PET in Recurrent Medullary Thyroid Carcinoma
    Verbeek, Hans H. G.
    Plukker, John T. M.
    Koopmans, Klaas Pieter
    de Groot, Jan Willem B.
    Hofstra, Robert M. W.
    Kobold, Anneke C. Muller
    van der Horst-Schrivers, Anouk N. A.
    Brouwers, Adrienne H.
    Links, Thera P.
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (12) : 1863 - 1871
  • [7] Comparison of 18F-FDG PET-CT and 68GA-PSMA PET-CT in Hepatocellular Carcinoma
    Shamim, S.
    Arora, G.
    Hussain, J.
    Gupta, S.
    Shalimar
    Gamanagatti, S.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S556 - S557
  • [8] Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
    Giorgio Treglia
    Paola Castaldi
    Maria Felicia Villani
    Germano Perotti
    Chiara de Waure
    Angelina Filice
    Valentina Ambrosini
    Nadia Cremonini
    Monica Santimaria
    Annibale Versari
    Stefano Fanti
    Alessandro Giordano
    Vittoria Rufini
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 569 - 580
  • [9] Comparison of 68Ga-somatostatin Analogues, 18F-DOPA and 18F-FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma
    Treglia, Giorgio
    Castaldi, Paola
    Villani, Maria Felicia
    Filice, Angelina
    Ambrosini, Valentina
    Cremonini, Nadia
    Salvo, Diana
    Fanti, Stefano
    Giordano, Alessandro
    Rufini, Vittoria
    PANCREAS, 2012, 41 (02) : 349 - 350
  • [10] Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
    Treglia, Giorgio
    Castaldi, Paola
    Villani, Maria Felicia
    Perotti, Germano
    de Waure, Chiara
    Filice, Angelina
    Ambrosini, Valentina
    Cremonini, Nadia
    Santimaria, Monica
    Versari, Annibale
    Fanti, Stefano
    Giordano, Alessandro
    Rufini, Vittoria
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (04) : 569 - 580